Background/Aims: Infectious complications are major concerns when treating patients with inflammatory bowel disease (IBD). This study evaluated clinical differences across countries/regions in the management of infectious diseases in patients with IBD.Methods: A multinational online questionnaire survey was administered to participants at the 8th meeting of the Asian Organization for Crohn’s and Colitis. The questionnaire included questions regarding surveillance, diagnosis, management, and prevention of infection in patients with IBD.Results: A total of 384 physicians responded to the questionnaire. The majority of Korean (n = 70, 63.6%) and Chinese (n = 51, 51.5%) physicians preferred vancomycin to metronidazole in the treatment of <i>Clostridium difficile</i> infection, whereas more than half of the Japanese physicians (n = 62, 66.7%) preferred metronidazole. Physicians in Korea (n = 88, 80.0%) and China (n = 46, 46.5%) preferred a 3-month course of isoniazid and rifampin to treat latent tuberculosis infection, whereas most physicians in Japan (n = 71, 76.3%) favored a 9-month course of isoniazid. Most Korean physicians (n = 89, 80.9%) recommended hepatitis B virus (HBV) vaccination in patients lacking HBV surface antigen, whereas more than half of Japanese physicians (n = 53, 57.0%) did not consider vaccination.Conclusions: Differences in the diagnosis, prevention, and management of infections in patients with IBD across countries/regions reflect different prevalence rates of infectious diseases. This survey may broaden understanding of the real-world clinical settings across Asian countries/regions and provide information for establishing practical guidelines to manage patients with IBD.

colitis (UC) and Crohn' s disease (CD). The pathogenesis of IBD is not well established but multiple factors, including genetic, immunologic, microbial, and environmental factors, might comprehensively develop and aggravate IBD. 1 Patients with moderate-to-severe IBD are required immunomodulators (IMMs), biologics, or small molecule therapies and have high risks of hospitalization or surgery. It is important to predict the outcome of IBD, determine its treatment, and reassess the strategy according to the expected outcome.Arthritis is one of the extragastrointestinal manifestations that can be observed in patients with IBD. Arthritis in IBD patients was divided into 2 different clinical patterns: peripheral